Special consideration for pain management in patients with cancer.
OptumRx’s most recent pipeline outlook for 2020 reveals key therapeutic areas in the lineup.
Pfizer announced the introduction of 3 new oncology biosimilars to the US market at a substantially discounted price.
FDA approval decision expected in the second quarter of 2020.
Proton pump inhibitors (PPIs) may be linked to concentration and memory problems in individuals with a history of breast cancer.
Overall cancer death rates declined by 29% over a 26-year time period, with the largest single-year drop on record reported from 2016 to 2017.
Fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo and AstraZeneca) is a new treatment option for patients with HER2-positive breast cancer who have progressed after 2 or more prior regimens.
Approximately 1 in 8 women living in the United States will develop an invasive form of breast cancer at some point in her life
Prostate cancer is the second most common cancer in men after skin cancer.
Various factors can affect a patient’s survival rate.